Literature DB >> 20452222

Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.

Maria Elena Meza-Avina1, Lianhu Wei, Yan Liu, Ewa Poduch, Angelica M Bello, Ram K Mishra, Emil F Pai, Lakshmi P Kotra.   

Abstract

In recent years, orotidine-5'-monophosphate decarboxylase (ODCase) has gained renewed attention as a drug target. As a part of continuing efforts to design novel inhibitors of ODCase, we undertook a comprehensive study of potent, structurally diverse ligands of ODCase and analyzed their structural interactions in the active site of ODCase. These ligands comprise of pyrazole or pyrimidine nucleotides including the mononucleotide derivatives of pyrazofurin, barbiturate ribonucleoside, and 5-cyanouridine, as well as, in a computational approach, 1,4-dihydropyridine-based non-nucleoside inhibitors such as nifedipine and nimodipine. All these ligands bind in the active site of ODCase exhibiting distinct interactions paving the way to design novel inhibitors against this interesting enzyme. We propose an empirical model for the ligand structure for rational modifications in new drug design and potentially new lead structures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452222      PMCID: PMC3124134          DOI: 10.1016/j.bmc.2010.04.017

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  47 in total

1.  Electrostatic stress in catalysis: structure and mechanism of the enzyme orotidine monophosphate decarboxylase.

Authors:  N Wu; Y Mo; J Gao; E F Pai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 2.  Inhibitors of de novo nucleotide biosynthesis as drugs.

Authors:  Richard I Christopherson; Stephen D Lyons; Paul K Wilson
Journal:  Acc Chem Res       Date:  2002-11       Impact factor: 22.384

3.  Nifedipine and nimodipine competitively inhibit uridine kinase and orotidine-phosphate decarboxylase: theoretical relevance to poor outcome in stroke.

Authors:  T Najarian; T W Traut
Journal:  Neurorehabil Neural Repair       Date:  2000       Impact factor: 3.919

Review 4.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Contribution of enzyme-phosphoribosyl contacts to catalysis by orotidine 5'-phosphate decarboxylase.

Authors:  B G Miller; M J Snider; S A Short; R Wolfenden
Journal:  Biochemistry       Date:  2000-07-18       Impact factor: 3.162

Review 6.  Catalytic proficiency: the unusual case of OMP decarboxylase.

Authors:  Brian G Miller; Richard Wolfenden
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

7.  Studies on a pyrimidine phosphoribosyltransferase from murine leukemia P1534J. Partial purification, substrate specificity, and evidence for its existence as a bifunctional complex with orotidine 5-phosphate decarboxylase.

Authors:  P Reyes; M E Guganig
Journal:  J Biol Chem       Date:  1975-07-10       Impact factor: 5.157

8.  Identification of active antiviral compounds against a New York isolate of West Nile virus.

Authors:  John D Morrey; Donald F Smee; Robert W Sidwell; Christopher Tseng
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 5.970

9.  Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase.

Authors:  J Krungkrai; S R Krungkrai; K Phakanont
Journal:  Biochem Pharmacol       Date:  1992-03-17       Impact factor: 5.858

10.  Biochemistry and biological effects of the pyrazofurins (pyrazomycins): initial clinical trial.

Authors:  G E Gutowski; M J Sweeney; D C DeLong; R L Hamill; K Gerzon; R W Dyke
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

View more
  5 in total

1.  The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism.

Authors:  Steve Poirier; Samaneh Samami; Maya Mamarbachi; Annie Demers; Ta Yuan Chang; Dennis E Vance; Grant M Hatch; Gaétan Mayer
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

2.  Novel interactions of fluorinated nucleotide derivatives targeting orotidine 5'-monophosphate decarboxylase.

Authors:  Melissa Lewis; Maria Elena Meza-Avina; Lianhu Wei; Ian E Crandall; Angelica Mara Bello; Ewa Poduch; Yan Liu; Christopher J Paige; Kevin C Kain; Emil F Pai; Lakshmi P Kotra
Journal:  J Med Chem       Date:  2011-03-21       Impact factor: 7.446

3.  Atomic resolution structure of the orotidine 5'-monophosphate decarboxylase product complex combined with surface plasmon resonance analysis: implications for the catalytic mechanism.

Authors:  Masahiro Fujihashi; Kazuya Mito; Emil F Pai; Kunio Miki
Journal:  J Biol Chem       Date:  2013-02-10       Impact factor: 5.157

4.  The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors.

Authors:  Yu-Jin Kim; Beatrice Cubitt; Emily Chen; Mitchell V Hull; Arnab K Chatterjee; Yingyun Cai; Jens H Kuhn; Juan C de la Torre
Journal:  Antiviral Res       Date:  2019-07-11       Impact factor: 5.970

5.  Stereocontrolled Debenzylative Cycloetherification Reaction as a Route to Enantiopure C-Furanosides with Amino Substituents in the Side Chain.

Authors:  Karolina Tiara; Mykhaylo A Potopnyk; Paweł Świder; Sławomir Jarosz
Journal:  J Org Chem       Date:  2020-02-05       Impact factor: 4.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.